Product Name: PAK1 (420-426) pT423
Product Number: PE-04AOH95
Size: | 200 µg | | Price: | 42.00 |
| 1 mg | | $US | 84.00 |
Peptide Name: PAK1 (420-426) pT423
Product Use: Services as a blocking peptide for use with the PAK1-pT423 rabbit polyclonal antibody (Cat. No.: AB-PK749) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. T423 phosphorylation stimulates phosphotransferase activty and interaction with CDC42.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: KRS-pT-MVG
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated
Peptide Molecular Mass Calculated: 1031.14 Da
Peptide Purity Percent after Synthesis and Purification: >95
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: PAK1 - pT423 phosphosite-specific antibody (Cat. No.: AB-PK749) Scientific Background: PAK1 is a protein-serine/threonine kinase that is a member of the STE group of protein kinases in the STE20 family, and PAKA subfamily. This kinase is highly expressed and widely distributed in most tested human tissues. PAK1 has been implicated in the regulation of cytoskeletal organization, and cell proliferation and survival, morphology, motility and transformation. Binding of GTP-bound Cdc42 or Rac1 to the autoregulatory region at the N-terminus of PAK1 releases monomers from the autoinhibited dimer, enables phosphorylation at T423 and activation of its phosphotransferase activity. It is also activated by binding to GTP-bound Cdc42, independent of the phosphorylation state of T423. Phosphorylation of S144, S149, and T423 increases PAK1's phosphotransferase activity, whereas phosphorylation of T84 (by OXSR1) and Y212 inhibits its phosphotransferase activity. Phosphorylation of S21 inhibits binding of Nck and PIX. PAK1 may be a therapeutic target in B-Raf wild-type melanoma. Knockdown of PAK1 has been shown to inhibit the proliferation of mutant KRAS colon cancer cells.